Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date.

Araris Biotech is a biotech company specializing in the development of targeted antibody-drug conjugates. Their innovative platform allows for more effective and less toxic cancer therapies. The company is focused on advancing its pipeline through strategic partnerships. Araris is committed to improving patient outcomes in oncology.

Araris Biotech Closes $24 Million Financing Round

Description

Company Information

Related People

Funding Insights

Araris Biotech Closes $24 Million Financing Round

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information